Printer Friendly

Ariosa Diagnostics, Fleury Medicina e Saude to co-market Harmony prenatal test in Brazil.

M2 PHARMA-September 13, 2013-Ariosa Diagnostics, Fleury Medicina e Saude to co-market Harmony prenatal test in Brazil(C)2013 M2 COMMUNICATIONS

13 September 2013 - US molecular diagnostics company Ariosa Diagnostics said yesterday it had struck a deal with Fleury Medicina e Saude to sell the Harmony prenatal test in Brazil.

The Harmony evaluates the risk of fetal chromosome conditions, including Down syndrome, in pregnant women. It also features an option for X and Y chromosome analysis, giving information on sex chromosome conditions, such as Monosomy X or Klinefelter's syndrome, and fetal sex.

The product can be used for any singleton or twin pregnancy, including those conceived by IVF. The test is performed as early as 10 weeks of pregnancy.

The assay has been examined in more than 30,000 pregnant women, making it the most validated cell-free DNA test available, Ariosa noted.

((Comments on this story may be sent to

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:3BRAZ
Date:Sep 13, 2013
Previous Article:DiscoveRx introduces human primary cell-based assay platform for oncology research.
Next Article:Natural Molecular launches diagnostic molecular tests for women's preventive healthcare.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters